Abstract
The term “cancers of unknown primary site” (CUP) is usually associated with metastatic lesions for which a primary site of origin has not been identified (Pavlidis et al., Eur J Cancer 39(14):1990–2005, 2003). In approximately 3% of all adult patients with carcinomas, the site of origin is not identified. Pediatric patients also present with metastatic tumors that have no identifiable primary. The distribution in children includes similar “adult-type” carcinomas, but also embryonal cancers such as rhabdomyosarcoma and neuroblastoma (Kuttesch et al., Cancer 75(1):115–121, 1995). The strategy must include diagnostic imaging studies and molecular profiling techniques that may identify the tissue of origin. It is not clear if these techniques can direct treatment that may improve outcome. In the case of pediatric tumors of unknown primary site, the introduction of more modern imaging and molecular techniques has reduced the incidence of “true” pediatric CUPs. In 2011, the pediatric oncologist seeking to identify the site of origin of these unusual tumors has more advantages with improved imaging and molecular pathology techniques. CUPs provide great challenges for the pediatric oncologist. We hope to present some common sense strategies that might prove beneficial. We caution everyone that given no data, the clinician must be imaginative.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Altman E, Cadman E (1986) An analysis of 1539 patients with cancer of unknown primary site. Cancer 57(1):120–124
Bohuslavizki KH, Klutmann S et al (2000) FDG PET detection of unknown primary tumors. J Nucl Med 41(5):816–822
Bosl GJ, Ilson DH et al (1994) Clinical relevance of the i(12p) marker chromosome in germ cell tumors. J Natl Cancer Inst 86(5):349–355
Briasoulis E, Pavlidis N (1997) Cancer of unknown primary origin. Oncologist 2(3):142–152
Briasoulis E, Pavlidis N et al (2009) Cancers of unknown primary site: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20(Suppl 4):154–155
French CA, Kutok JL et al (2004) Midline carcinoma of children and young adults with NUT rearrangement. J Clin Oncol 22(20):4135–4139
Hainsworth JD, Rubin MD et al (2013) Molecular gene profiling to predict the tissue of origin and to direct site-specific therapy in patients with carcinoma of unknown primary site – a prospective trial of the Sarah Cannon Research Institute. J Clin Oncol 31(2):217–223
Horlings HM, van Laar RK et al (2008) Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary. J Clin Oncol 26(27):4435–4441
Kuttesch JF Jr, Parham DM et al (1995) Embryonal malignancies of unknown primary origin in children. Cancer 75(1):115–121
MacReady N (2010) NICE issues guidance on cancer of unknown primary. Lancet Oncol 11(9):824
Maisey MN, Ellam SV (1984) Investigating the adenocarcinoma of unknown origin (ACUP): a cost benefit analysis. Rev Epidemiol Sante Publique 32(1):57–61
Neumann KH, Nystrom JS (1982) Metastatic cancer of unknown origin: nonsquamous cell type. Semin Oncol 9(4):427–434
Pavlidis N (2003) Cancer of unknown primary: biological and clinical characteristics. Ann Oncol 14(Suppl 3):iii11–iii18
Pavlidis N, Fizazi K (2009) Carcinoma of unknown primary (CUP). Crit Rev Oncol Hematol 69(3):271–278
Pavlidis N, Pentheroudakis G (2010) Cancer of unknown primary site: 20 questions to be answered. Ann Oncol 21(Suppl 7):vii303–vii307
Pavlidis N, Briasoulis E et al (2003) Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 39(14):1990–2005
Pavlidis N, Hansen H et al (2010) ESMO clinical practice guidelines: development, implementation and dissemination. Ann Oncol 21(Suppl 5):v7–v8
Schapira DV, Jarrett AR (1995) The need to consider survival, outcome, and expense when evaluating and treating patients with unknown primary carcinoma. Arch Intern Med 155(19):2050–2054
Strnad CM, Grosh WW et al (1989) Peritoneal carcinomatosis of unknown primary site in women. A distinctive subset of adenocarcinoma. Ann Intern Med 111(3):213–217
Talantov D, Baden J et al (2006) A quantitative reverse transcriptase-polymerase chain reaction assay to identify metastatic carcinoma tissue of origin. J Mol Diagn 8(3):320–329
Varadhachary GR, Rabe MN (2009) Gene expression profiling in cancers of unknown primary. J Clin Oncol 27(25):e85–e86, author reply e87–88
Varadhachary GR, Talantov D et al (2008) Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol 26(27):4442–4448
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Olson, T.A. (2022). Tumors of Unknown Primary Site. In: Schneider, D.T., Brecht, I.B., Olson, T.A., Ferrari, A. (eds) Rare Tumors in Children and Adolescents. Pediatric Oncology. Springer, Cham. https://doi.org/10.1007/978-3-030-92071-5_46
Download citation
DOI: https://doi.org/10.1007/978-3-030-92071-5_46
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-92070-8
Online ISBN: 978-3-030-92071-5
eBook Packages: MedicineMedicine (R0)